Can HealthEquity (HQY) Stock Reach $120?

HealthEquity, Inc. (HQY), the Draper, Utah-based administrator of health savings accounts (HSAs) and other consumer-directed benefits, has become a frequent subject of one pointed investor question: can the stock reach $120? With shares trading near $97 and the average Wall Street price target sitting just below that round-number milestone, the question is both realistic and consequential. The answer depends on whether the company can push through its prior record high and sustain the growth that has made it a favorite among analysts.

Key Takeaways

• The selected price target is $120 per share, roughly 24% above the latest trading level near $97 and above the 52-week high of $107.62.
• Analyst consensus is a Strong Buy, with an average 12-month price target around $119 and a high estimate of $142.
• Rising HSA accounts and assets, expanding margins, and share buybacks are the strongest bullish drivers.
• The biggest obstacles are interest-rate sensitivity on custodial cash and the need to clear the $107–$108 record-high resistance zone.
• Near-term support sits around $93–$95, with the $107–$108 area acting as the critical hurdle before $120 becomes plausible.

Why Investors Are Watching the $120 Level

$120 is more than a convenient round number. It aligns almost exactly with the Street's average price target, which has hovered near $119 to $121 in recent months. It also sits comfortably above the stock's 52-week high of $107.62, meaning the level would require a genuine breakout to new highs rather than a simple rebound. That combination makes $120 a meaningful barometer: reaching it would confirm the bull case, while stalling below it would leave the stock range-bound.

Current Market Position

As of the most recent session, HealthEquity traded near $97, with after-hours quotes edging slightly lower. The stock has spent the past year between roughly $72.76 and $107.62, putting the current price in the upper-middle portion of that range. The company generated about $1.36 billion in trailing revenue and roughly $236 million in net income, with earnings per share (EPS) of $2.77 and a price-to-earnings (P/E) ratio near 35. For context, a P/E ratio measures how much investors pay for each dollar of earnings.

What Could Drive the Next Leg Higher

HealthEquity's core business remains its strongest argument. The company administers roughly 10.7 million HSAs, and total HSA assets grew to about $37.9 billion as of mid-2026, up 14% year over year. HSAs are tax-advantaged accounts that allow consumers to save and invest for healthcare costs, and the long-term shift toward high-deductible health plans and consumer-directed benefits continues to expand the addressable market.

Profitability is also improving. Management raised its fiscal 2027 guidance after a strong quarter, projecting full-year revenue between roughly $1.405 billion and $1.415 billion. Expanding margins, disciplined expense management, and an active share repurchase program that has reduced diluted share count all provide underlying support for earnings growth. In a market rewarding profitable, cash-generative businesses, that profile matters.

What Could Prevent the Move

The most significant headwind is interest-rate sensitivity. A meaningful portion of HealthEquity's revenue comes from the interest earned on custodial cash deposits held in HSAs. In a lower-rate environment, that yield compresses, and some analysts have flagged this as a reason the multiple could face pressure. Competition in the HSA and benefits-administration space is another persistent concern, as is regulatory uncertainty around healthcare policy.

Valuation adds a further complication. At a P/E near 35, the stock already embeds expectations for continued double-digit earnings growth. If that growth merely matches, rather than exceeds, consensus forecasts, investors may be unwilling to pay a higher multiple to push shares toward $120.

Analyst Opinions and Price Targets

Wall Street's view is broadly constructive. Analysts polled by S&P Global assign the stock a consensus "Strong Buy" rating with an average 12-month price target near $119. Estimates range from roughly $105 at the low end to $142 at the high end, the latter reflecting Deutsche Bank's August 2026 increase from $135 to $142. Wells Fargo carries a $125 target, while firms such as RBC Capital and BMO Capital hold targets in the $105–$108 range. The concentration of targets just above and below $120 explains why that level has become the focal point of the debate.

Technical Levels That Matter

From a technical analysis standpoint, the $107–$108 zone is the defining obstacle. That area marks the 52-week high and represents a supply zone where sellers previously emerged. A decisive move above it on sustained volume would establish a new uptrend and open the path toward the $120 psychological milestone. On the downside, the $93–$95 area has functioned as near-term support, with the low-$80s serving as a deeper floor. As long as the stock holds above its recent support zone, the setup favors a gradual grind toward the prior highs rather than a sharp reversal.

AI Daily Buy/Sell Signals

Traders tracking HealthEquity's progress toward $120 may find value in AI Daily Buy/Sell Signals. This product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The signals are designed to help traders discover new opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual screening allows. For those watching key levels such as the $107–$108 resistance zone, these automated insights can offer a useful complement to fundamental research.

Final Assessment

Reaching $120 is realistic but not guaranteed. The combination of a Strong Buy consensus, an average price target essentially at that level, growing HSA assets, and improving margins provides a credible fundamental foundation. Yet the stock must first break decisively above its $107–$108 record high, a move that likely requires continued earnings beats and a stabilizing rate outlook rather than a compression in valuation. Investors should monitor quarterly HSA account and asset growth, custodial yield trends, and price action around the $107–$108 resistance level. A sustained breakout there would meaningfully improve the odds that the $120 question is answered in the affirmative.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations